23:17 , Sep 29, 2017 |  BioCentury  |  Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
23:16 , Jul 13, 2017 |  BC Week In Review  |  Clinical News

Apogenix's asunercept receives PRIME designation for glioblastoma

In late May, Apogenix AG (Heidelberg, Germany) said EMA granted PRIority MEdicines (PRIME) designation to asunercept (APG101, CAN-008) to treat glioblastoma. The designation is based on data from a Phase II trial in which asunercept...
22:03 , May 23, 2017 |  BC Extra  |  Financial News

Lapam leads Canbridge's $25M series B

Canbridge Life Sciences Ltd. (Beijing, China) raised $25 million in a series B led by Lapam Capital. Also participating were Qiming Venture Partners, Yuanming Capital, Yanyuan Capital, Biossom Investment Management and WuXi AppTec Co. Ltd....
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

APG101: Phase I/II started

Canbridge began a Taiwanese Phase I/II trial to evaluate once-weekly 200 and 400 mg IV CAN-008 plus temozolomide in about 55 patients with newly diagnosed GBM. The trial comprises an open-label, dose-escalation Phase I portion...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

APG101: Phase I/II start

This month, Canbridge will begin a Phase I/II trial evaluating CAN-008 plus temozolomide in about 55 patients. The trial comprises an open-label, dose-escalation Phase I portion and a double-blind, placebo-controlled Phase II portion. Canbridge has...
07:00 , Aug 4, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: FAS receptor (CD95); CD95 ligand

Autoimmune disease INDICATION: Systemic lupus erythematosus (SLE) Patient sample and mouse studies suggest inhibitors of CD95-mediated calcium signaling could help treat SLE. In patient serum and skin samples, levels of soluble CD95 ligand were higher...
07:00 , Jul 14, 2016 |  BC Innovations  |  Product R&D

Apogenix's hex on TNF

TNF receptor superfamily members include well-validated cancer and immuno-oncology drug targets, but creating high-potency agonists is made difficult by the molecules' unique mode of ligand binding. Apogenix AG is designing compounds that more closely mimic...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Company News

R-Biopharm, Apogenix deal

R-Biopharm and Apogenix partnered to develop companion diagnostics for Apogenix’s APG101 . APG101 is in development to treat solid tumors and malignant hematological diseases and is slated to begin a Phase III trial next year...
01:19 , Jul 16, 2015 |  BC Extra  |  Company News

Canbridge gains China rights to APG101

Apogenix GmbH (Heidelberg, Germany) granted Canbridge Life Sciences Ltd. (Beijing, China) exclusive rights to APG101 in China, Macao and Hong Kong to treat glioblastoma multiforme (GBM), with options in additional indications. Apogenix CEO Thomas Hoeger...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Apocept: Additional Phase II data

Additional data from an open-label, international Phase II trial in 84 patients with recurrent GBM showed that once-weekly IV APG101 plus radiotherapy as second-line treatment significantly improved median OS in patients who were positive for...